Latest Breaking News On - Ulf hannelius - Page 9 : comparemela.com

Diamyd Medical contracts global CRO for Phase III trial with the diabetes vaccine Diamyd STOCKHOLM, April 15, 2021 /PRNewswire/ Diamyd Medical has contracted the global contract research organization (CRO) ICON plc for DIAGNODE-3, a placebo-controlled Phase III precision medicine trial with the diabetes vaccine Diamyd . The trial is designed to confirm the efficacy and safety of Diamyd in individuals recently diagnosed with type 1 diabetes who carry the genetically defined haplotype HLA DR3-DQ2. The trial is expected to begin recruiting patients later this year. We have gotten to know ICON as a very skilled and committed collaboration partner during the preparation of our Phase III trial, says Ulf Hannelius, CEO of Diamyd Medical. Now we take the next critical step together with a focus on precision medicine for type 1 diabetes, and with over SEK 200 million in cash, we can move full speed ahead with getting the trial started in all countries and clinics.

United statesUppsala lanUlf hanneliusContract research organisationsCompany european phase iibCompany certified adviserUppsala university hospitalCoordinating investigatorProfessor johnny ludvigssonCompetent authoritiesEthics committeesEuropean phaseUppsala universityDiamyd medicalNextcell pharmaNasdaq first north growth market